Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03334487
Title Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
Recruitment Withdrawn
Gender both
Phase Phase III
Variant Requirements No
Sponsors AbbVie
Age Groups: senior | adult
Covered Countries USA | GBR | DEU | CAN | AUS

No variant requirements are available.